

TrakCel completes Rights issue. Appoints US CEO

CARDIFF, WALES, UK – 15th June 2016. TrakCel, a provider of supply chain technology to aid in the processing of regenerative therapies, has successfully completed a rights issue leading to significant new hires and appointed a new US Chief Executive Officer with regional responsibility for the company's fast growing US and Canadian activities.

The successful completion of the company's rights issue follows a series of significant new contract wins in the USA and allows the business to further enhance its technology platform and progress plans to expand its US and Canadian presence. Over 80% of the Rights Issue was taken up by virtue of subscription rights, with the remainder allotted to general investor demand without those rights. Broad based demand for the issue was received, reflecting the company's diverse investor base and continued buoyancy in its core Cell, Gene and Immunotherapy markets.

"We are extremely pleased with the outcome of the Rights Issue. This success is a welcome vote of confidence from our existing shareholders as well as new incoming investors in support of our long-term strategic vision in the Cell, Gene and Immunotherapy markets." stated Keren Winmill, Chairman.

TrakCel also today announced the appointment of Jim Langford as chief executive of the company's rapidly evolving North American operations. Mr. Langford has been a leader in the biopharmaceutical clinical development industry for over 25 years, having founded and managed several companies to leadership positions in the industry including DataLabs, Inc. an electronic data management company, where he served as President and CEO from 2001 until leading the sale of the business to Clinphone, PLC, in 2006, which was subsequently sold to PAREXEL International.

Prior to founding DataLabs, Jim created and lead a Contract Research Organization, The PHOENIX, where they successfully managed over 300 clinical studies in all therapeutic areas for the pharmaceutical, biotechnology and medical device industries, over a 16 year period. Most recently, Mr. Langford was a principal at White Star Consulting, where he led their practice in the cell therapy industry.

Keren Winmill, Chairman, was quoted as saying "We are thrilled to have someone of Jim's experience and background to guide TrakCel in meeting our aggressive ambitions for US growth and achieving our goal of delivering a world class technology platform."

Specialist law firm Greenaway Scott advised TrakCel on the rights issue. Nigel Greenaway of Greenaway Scott, said: "It is both interesting and exciting to be part of TrakCel's journey. We have supported the company from its inception as a spin-out company and are delighted to continue working along-side them through this period of growth and development. TrakCel is also a good example of the development and growth of the life science sector in Wales."

The announcement is part of a series of strategic developments within the business as it builds upon its Clinical and commercial success across the globe.



About TrakCel

TrakCel's cell, gene and immunotherapy management solution improves clinical study efficacy and accelerates product scale-up/scale-out by implementing communications technology to integrate the supply chain from end-to-end. The technology provides interactive instructions to professionals across the supply chain and gives stakeholders on-demand visibility of procedural results and chain-of-custody data for immediate traceability, validation and compliance audits.

TrakCel technology has been adopted by GlaxoSmithKline and other leaders in the cell therapy industry. TrakCel is headquartered in Cardiff, Wales.

TrakCel Ltd.

11 Raleigh Walk

Brigantine Place Cardiff,

UK, CF10 4LN

www.trakcel.com

Jon Curley, Public Relations

+44 (0)2920 483729

Jon.curley@trakcel.com